adalimumab
abbvie
['crohn', 'adalimumab']
adalimumab de-escalation in persistent remission of crohns. #uegw2022
op106 increased vs conventional adalimumab dose intervals in crohn s disease in stable remission: the randomised controlled ladi trial
see our clinical experience in 
IBD Research Group, Badalona. Catalonia / Grup de Recerca en Malalties Inflamatòries Intestinals (GReMII). CIBERehd